European Journal of Clinical Nutrition (2010) 64, 636–643; doi:10.1038/ejcn.2010.19; published online 10 March 2010
Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial
Y Kadooka1, M Sato2, K Imaizumi2, A Ogawa1, K Ikuyama3, Y Akai3, M Okano3, M Kagoshima4 and T Tsuchida5
1Technology and Research Institute, Snow Brand Milk Products Co. Ltd., Saitama, Japan
2Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, Fukuoka, Japan
3Nippon Milk Community Co. Ltd., Saitama, Japan
4Department of Pharmacy, Faculty of Pharmacy, Iwaki Meisei University, Fukushima, Japan
5Isogo Central and Neurosurgical Hospital, Kanagawa, Japan
Correspondence: Y Kadooka, Technology & Research Institute, Snow Brand Milk Products Co. Ltd., 1–1–2 Minamidai, Kawagoe, Saitama, 350–1165, Japan. E-mail: email@example.com
Received 14 August 2009; Revised 13 November 2009; Accepted 11 January 2010; Published online 10 March 2010.
Top of page
Background/Objectives: In spite of the much evidence for the beneficial effects of probiotics, their anti-obesity effects have not been well examined. We evaluated the effects of the probiotic Lactobacillus gasseri SBT2055 (LG2055) on abdominal adiposity, body weight and other body measures in adults with obese tendencies.
Subjects/Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled intervention trial. Subjects (n=87) with higher body mass index (BMI) (24.2–30.7 kg/m2) and abdominal visceral fat area (81.2–178.5 cm2) were randomly assigned to receive either fermented milk (FM) containing LG2055 (active FM; n=43) or FM without LG2055 (control FM; n=44), and were asked to consume 200 g/day of FM for 12 weeks. Abdominal fat area was determined by computed tomography.
Results: In the active FM group, abdominal visceral and subcutaneous fat areas significantly (P<0.01) decreased from baseline by an average of 4.6% (mean (confidence interval): −5.8 (−10.0, −1.7) cm2) and 3.3% (−7.4 (−11.6, −3.1) cm2), respectively. Body weight and other measures also decreased significantly (P<0.001) as follows: body weight, 1.4% (−1.1 (−1.5, −0.7) kg); BMI, 1.5% (−0.4 (−0.5, −0.2) kg/m2); waist, 1.8% (−1.7 (−2.1, −1.4) cm); hip, 1.5% (−1.5 (−1.8, −1.1) cm). In the control group, by contrast, none of these parameters decreased significantly. High-molecular weight adiponectin in serum increased significantly (P<0.01) in the active and control groups by 12.7% (0.17 (0.07, 0.26) μg/ml) and 13.6% (0.23 (0.07, 0.38) μg/ml), respectively.
Conclusion: The probiotic LG2055 showed lowering effects on abdominal adiposity, body weight and other measures, suggesting its beneficial influence on metabolic disorders.
Keywords: abdominal fat; body weight and measures; computed tomography; probiotics; cultured milk products; adiponectin